Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.

ABSTRACT:

Background

Tafenoquine, a single-dose therapy for Plasmodium vivax malaria, has been associated with relapse prevention through the clearance of P. vivax parasitemia and hypnozoites, termed "radical cure."

Methods

We performed a phase 3, prospective, double-blind, double-dummy, randomized, controlled trial to compare tafenoquine with primaquine in terms of safety and efficacy. The trial was conducted at seven hospitals or clinics in Peru, Brazil, Colombia, Vietnam, and Thailand and involved patients with normal glucose-6-phosphate dehydrogenase (G6PD) enzyme activity and female patients with moderate G6PD enzyme deficiency; all patients had confirmed P. vivax parasitemia. The patients were randomly assigned, in a 2:1 ratio, to receive a single 300-mg dose of tafenoquine or 1

SUBMITTER: Llanos-Cuentas A 

PROVIDER: S-EPMC6657225 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature